These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 21455728)

  • 1. AMP-activated protein kinase is activated in adipose tissue of individuals with type 2 diabetes treated with metformin: a randomised glycaemia-controlled crossover study.
    Boyle JG; Logan PJ; Jones GC; Small M; Sattar N; Connell JM; Cleland SJ; Salt IP
    Diabetologia; 2011 Jul; 54(7):1799-809. PubMed ID: 21455728
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pioglitazone stimulates AMP-activated protein kinase signalling and increases the expression of genes involved in adiponectin signalling, mitochondrial function and fat oxidation in human skeletal muscle in vivo: a randomised trial.
    Coletta DK; Sriwijitkamol A; Wajcberg E; Tantiwong P; Li M; Prentki M; Madiraju M; Jenkinson CP; Cersosimo E; Musi N; Defronzo RA
    Diabetologia; 2009 Apr; 52(4):723-32. PubMed ID: 19169664
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metformin increases AMP-activated protein kinase activity in skeletal muscle of subjects with type 2 diabetes.
    Musi N; Hirshman MF; Nygren J; Svanfeldt M; Bavenholm P; Rooyackers O; Zhou G; Williamson JM; Ljunqvist O; Efendic S; Moller DE; Thorell A; Goodyear LJ
    Diabetes; 2002 Jul; 51(7):2074-81. PubMed ID: 12086935
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Yam Gruel alone and in combination with metformin regulates hepatic lipid metabolism disorders in a diabetic rat model by activating the AMPK/ACC/CPT-1 pathway.
    Dai Y; Qiu C; Zhang D; Li M; Liu W
    Lipids Health Dis; 2024 Jan; 23(1):28. PubMed ID: 38273354
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FGF21 does not require adipocyte AMP-activated protein kinase (AMPK) or the phosphorylation of acetyl-CoA carboxylase (ACC) to mediate improvements in whole-body glucose homeostasis.
    Mottillo EP; Desjardins EM; Fritzen AM; Zou VZ; Crane JD; Yabut JM; Kiens B; Erion DM; Lanba A; Granneman JG; Talukdar S; Steinberg GR
    Mol Metab; 2017 Jun; 6(6):471-481. PubMed ID: 28580278
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metformin improves atypical protein kinase C activation by insulin and phosphatidylinositol-3,4,5-(PO4)3 in muscle of diabetic subjects.
    Luna V; Casauban L; Sajan MP; Gomez-Daspet J; Powe JL; Miura A; Rivas J; Standaert ML; Farese RV
    Diabetologia; 2006 Feb; 49(2):375-82. PubMed ID: 16395615
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The mechanisms of action of metformin.
    Rena G; Hardie DG; Pearson ER
    Diabetologia; 2017 Sep; 60(9):1577-1585. PubMed ID: 28776086
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparison of efficacy and safety of vildagliptin and gliclazide in combination with metformin in patients with Type 2 diabetes inadequately controlled with metformin alone: a 52-week, randomized study.
    Filozof C; Gautier JF
    Diabet Med; 2010 Mar; 27(3):318-26. PubMed ID: 20536495
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of AMP-activated protein kinase in mechanism of metformin action.
    Zhou G; Myers R; Li Y; Chen Y; Shen X; Fenyk-Melody J; Wu M; Ventre J; Doebber T; Fujii N; Musi N; Hirshman MF; Goodyear LJ; Moller DE
    J Clin Invest; 2001 Oct; 108(8):1167-74. PubMed ID: 11602624
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of efficacy and tolerability of gliclazide and metformin combination: a multicentric study in patients with type 2 diabetes mellitus uncontrolled on monotherapy with sulfonylurea or metformin.
    Pareek A; Chandurkar N; Zawar S; Agrawal N
    Am J Ther; 2010; 17(6):559-65. PubMed ID: 20093927
    [TBL] [Abstract][Full Text] [Related]  

  • 11. AMP-activated protein kinase is required for the lipid-lowering effect of metformin in insulin-resistant human HepG2 cells.
    Zang M; Zuccollo A; Hou X; Nagata D; Walsh K; Herscovitz H; Brecher P; Ruderman NB; Cohen RA
    J Biol Chem; 2004 Nov; 279(46):47898-905. PubMed ID: 15371448
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term efficacy and tolerability of add-on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetes.
    Charbonnel B; Schernthaner G; Brunetti P; Matthews DR; Urquhart R; Tan MH; Hanefeld M
    Diabetologia; 2005 Jun; 48(6):1093-104. PubMed ID: 15889234
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exenatide decreases hepatic fibroblast growth factor 21 resistance in non-alcoholic fatty liver disease in a mouse model of obesity and in a randomised controlled trial.
    Samson SL; Sathyanarayana P; Jogi M; Gonzalez EV; Gutierrez A; Krishnamurthy R; Muthupillai R; Chan L; Bajaj M
    Diabetologia; 2011 Dec; 54(12):3093-100. PubMed ID: 21956711
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adiponectin stimulates lipid metabolism via AMPK in rabbit blastocysts.
    Schindler M; Pendzialek M; Grybel KJ; Seeling T; Gürke J; Fischer B; Navarrete Santos A
    Hum Reprod; 2017 Jul; 32(7):1382-1392. PubMed ID: 28472298
    [TBL] [Abstract][Full Text] [Related]  

  • 15. X-3, a mangiferin derivative, stimulates AMP-activated protein kinase and reduces hyperglycemia and obesity in db/db mice.
    Han J; Yi J; Liang F; Jiang B; Xiao Y; Gao S; Yang N; Hu H; Xie WF; Chen W
    Mol Cell Endocrinol; 2015 Apr; 405():63-73. PubMed ID: 25681564
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Gliclazide and metformin combination in patients with type 2 diabetes. Preliminary data].
    Galeone F; Fiore G; Arcangeli A; Mannucci E
    Minerva Endocrinol; 1998 Sep; 23(3):71-5. PubMed ID: 10063324
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term effects on lipids and lipoproteins of pioglitazone versus gliclazide addition to metformin and pioglitazone versus metformin addition to sulphonylurea in the treatment of type 2 diabetes.
    Betteridge DJ; Vergès B
    Diabetologia; 2005 Dec; 48(12):2477-81. PubMed ID: 16283239
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metformin and salicylate synergistically activate liver AMPK, inhibit lipogenesis and improve insulin sensitivity.
    Ford RJ; Fullerton MD; Pinkosky SL; Day EA; Scott JW; Oakhill JS; Bujak AL; Smith BK; Crane JD; Blümer RM; Marcinko K; Kemp BE; Gerstein HC; Steinberg GR
    Biochem J; 2015 May; 468(1):125-32. PubMed ID: 25742316
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Metformin and AMPK: an old drug and a new enzyme in the context of metabolic syndrome].
    Santomauro Júnior AC; Ugolini MR; Santomauro AT; Souto RP
    Arq Bras Endocrinol Metabol; 2008 Feb; 52(1):120-5. PubMed ID: 18345405
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nateglinide or gliclazide in combination with metformin for treatment of patients with type 2 diabetes mellitus inadequately controlled on maximum doses of metformin alone: 1-year trial results.
    Ristic S; Collober-Maugeais C; Cressier F; Tang P; Pecher E
    Diabetes Obes Metab; 2007 Jul; 9(4):506-11. PubMed ID: 17587393
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.